INTRODUCTION
Human immunodeficiency virus types 1 and 2 (HIV-1, -2), the aetiological agents of AIDS, are retroviruses that replicate in CD4 ÷ T lymphocytes, monocytes and macrophages. Most lymphocyte-selected laboratory strains of HIV are cytopathic and we have compared the ability of a wide range ofCD4 ÷ cell lines to act as target cells in plaque assays. Such assays are useful for biological cloning of HIV and can be used in quantitative neutralization tests. HIV infection induces neutralizing antibodies (Weiss et al., 1985; Robert-Guroff et al., 1985; Harada et al., 1985) . It is not known whether antibodies that neutralize HIV infectivity in vitro provide an important mechanism of protection against disease. However, identification of viral components responsible for eliciting such antibodies will improve our understanding of the mechanisms of neutralization, and should aid the design of vaccines to HIV. Thus quantitative neutralization tests are required, not only for titrating antibodies, but also for analysing antigenic variation.
A number of assays for the measurement of neutralizing antibodies for HIV have been reported, using different parameters to measure the reduction of viral infectivity: reverse transcriptase (RT) (Matthews et al., 1986; Cheng-Mayer et al., 1988; Prince et al., 1987) , indirect immunofluorescence for viral antigens (Zagury et al., 1988) , p24 antigen levels (Looney et al., 1988) , syncytium formation (Weiss et al., 1985; Nara et al., 1987) , plaque formation by vesicular stomatitis virus (VSV) pseudotypes (Weiss et al., 1985 (Weiss et al., , 1986 , and non-specific chemical measurement of cell death by the incorporation of [3H]thymidine (Harada et al., 1986) or vital dyes such as tetrazolium salts leading to a colour change (Montefiori et al., 1988) . Most of these assays are quantal, registering whether infection has occurred. A quantitative assay is one where each viral particle multiplies and gives rise to a localized focus of infected cells giving rise to a visible plaque after a number of days in culture. These plaques should be the result of a 'onehit' process, and should therefore be clonal. Focal plaque assays for HIV-1 have been described by Harada et al. (1985 Harada et al. ( , 1986 and by Nara et al. (1987) . Here we evaluate a number of cell lines and methods and apply the plaque technique to measurement of neutralizing antibodies.
METHODS

Cells.
MT-4 and MT-2 cells are human T cell leukaemia cell lines, transformed by the human leukaemia virus type I (HTLV-I) genome (Harada et al., 1985) . Jurkat-tat cells are human T cell leukaemia cell lines transfected with the trans-activator gene (tat) of the HTLV-IIIB strain of HIV (Rosen et al., 1986) ; JM is a subclone of Jurkat cells. C8166 cells are a T cell line containing a genome of HTLV-I that expresses only the tat gene (Sodroski et al., 1984) . Hut 102 ceils were derived from a human cutaneous T cell lymphoma containing HTLV-I. CEM-4 cells (Foley et al., 1965) and a subclone CEMss (Nara et al., 1987) originate from a childhood acute T cell leukaemia. CEMx174 are a somatic cell hybrid of CEM and a B cell line (721.174) transformed by Epstein-Barr virus (EBV). Sup-T1 is a T lymphoma cell line expressing high levels of CD4 antigen (Smith et al., 1984) . H9 cells (Popovic et al., 1984) originate from a T cell leukaemia. Molt-4 cells originate from an acute lymphoblastic leukaemia (Minowada et al., 1972) ; clone 8 has been reported to have a greater sensitivity for HIV infection (M. Hayami, unpublished information). The cells were maintained in RPMI 1640 medium with 10% foetal calf serum (FCS).
Virus. All HIV and SIV stocks were prepared from the culture supernatants of chronically infected H9 cell cultures, 48 h after cocultivation of one part infected to four parts uninfected H9 cells. Tenfold serial dilutions of virus (50 ttl) were incubated with 100 ~tl of cells at 2 x 105/ml in microtitre plates at 37 °C for 7 days. The plates were scored for the presence or absence of syncytia, and the TCIDs0 values determined using the K/irber formula. All virus dilutions were tested in quadruplicate.
Plaque assay. Six-well tissue culture plates were treated with 50 ~tg/ml of poly-L-lysine for 1 h at room temperature. The wells were then washed three times with distilled water and left to dry in air. Cells were washed in serum-free medium twice and resuspended at a final cell concentration of 106 to 2 x 106/ml. The cells were then allowed to adsorb to the plates (1 ml/well) for 20 rain at room temperature. Unbound cells were subsequently removed by aspiration and the virus inoculum, in a volume of 500 ~tl, was allowed to adsorb for 1 h at 37 °C. The virus was removed and an agarose overlay consisting of 0.9~ Sea-plaque agarose (ICN) in RPMI 1640 with 20~ FCS was added gently to the monolayer. After the agarose medium had set, the plates were incubated at 37 °C for 3 days, when a second agarose overlay was added. Neutral red stain was added in the second agarose overlay to the C8166, Molt-4 clone 8 and MT-2 cells, at a final concentration of 0.00032~, incubated in the dark for 20 h and the plaques were counted using an inverted microscope.
HIV neutralization 103 TCID50 or plaque-forming units of HIV, VSV(HIV) pseudotype (Weiss et al., 1985 (Weiss et al., , 1986 , in a volume of 40 ~tl was incubated with 10 ~tl of a dilution of antibody or serum under test, and incubated at 37 °C for 1 h. The virus/antibody mixture was then assayed for residual infectivity in each of the following three assay systems.
Infection inhibition. The virus/antibody mixture was incubated with 100 ~tl of C8166 cells at a concentration of 2 x 10S/ml in 10 ~ FCS/RPMI per well of a 96-well microtitre plate, in quadruplicate. The wells were subsequently scored for the presence of syncytia (Clapham et al., 1987) and the final dilution of serum able to show 90 to 95 reduction of syncytia in the indicator cells was defined as the reciprocal neutralization titre.
Plaque assay. The virus/antibody mixture (50 ~tl) was made up to a final volume of 500 ~tl and added to a prepared MT-4 monolayer, incubated at 37 °C for 1 h, and an agarose overlay was then added as mentioned above.
Pseudotype assay. VSV pseudotypes enveloped in HIV glycoproteins were prepared and assayed as described previously (Dalgleish et al., 1984; Weiss et al., 1986) , using an adherent subline of CEM cells as targets for pseudotype infection.
RESULTS
A number ofT cell lines were compared for their sensitivity to HIV infection, as monitored by their ability to show a cytopathic effect with three strains of HIV. Two HIV-1 strains were examined, HTLV-IIIRF isolated from a Haitian patient (Popovic et al., 1984) and U445a from a Ugandan patient (Downing et al., 1984) , as well as the prototype HIV-2 isolate, LAV-2 ROD from an AIDS patient in Guinea Bissau (Clavel et al., 1986) . Table 1 shows that the cell lines showing the highest c.p.e, for all three strains of HIV tested were C8166 and MT-4. There was some variation in the TCIDs0 values obtained from the same cell lines obtained from different laboratories emphasizing the need for laboratories to work with the same clone of cells if results are to be compared.
All the cell lines positive for c.p.e, were tested for their ability to act as targets in a plaque assay, using an adaptation of a plaque assay reported by Harada et al. (1985) . Plates were monitored for plaque formation at 5 to 6 days post-infection (p.i.). The only cell line able to produce plaques visible by eye were MT-4 cells (Fig. 1) . However, the C8166, MT-2 and Molt-4 clone 8 cell lines did produce microscopic plaques, which could be visualized by staining with neutral red; the plaques could be counted using an inverted microscope (data not shown).
Fig. 1. MT-4 plaque assay. HTLV-IIIB-induced plaques on poly-t,-lysine-adhered MT-4 cells. Serial dilution of HTLV-IIIB showing a dose-response relationship for plaque production.
Upper row left to right shows: well 1, too many to count; well 2, too many to count; well 3, 400 plaques. Lower row left to right shows: well 4, 36 plaques; well 5, three plaques; well 6, uninfected control cells. A  B  C  1  160  160  40  320  320  320  80  80  320  2  80  80  20  20  10  80  80  40  160  3  40  40  20  20  10  20  < 10  < 10  20  4  40  40  20  20  10  40  < 10  10  40  5  320  320  40  80  80  80  320  320  320  6  160  160  20  320  160  160  40  40  320  7t  <10  <10  <10  <10  <10  <10  <10  <10 t Serum no. 7 is seronegative for HIV and serves as an internal specificity control.
T a b l e 1. Titration of H I V on T lymphocytic cell lines
The MT-4 plaque assay was found to be as sensitive as TCIDs0 assays with C8166 and MT-4 cells using the appearance of syncytia as an indicator of HIV infection (Clapham et al., 1987) . Table 2 shows that a wide range of strains of HIV-I, HIV-2 and SIV gave similar results. Since the MT-4 plaques could be visualized by eye, this test was chosen for further evaluation alongside two neutralization assays routinely used in this laboratory, the VSV pseudotype assay (Weiss et al., 1985 (Weiss et al., , 1986 ) and the inhibition of syncytium formation using the C8166 cell line (Clapham et al., 1987) . Table 3 shows the neutralization titres of six human sera selected for the WHO panel on standardization of neutralization, for three strains of HIV-1 using the three neutralization tests. DISCUSSION Our studies revealed considerable variation in TCIDso titres of HIV-1 and HIV-2 on nine different CD4 + cell lines and on different sublines (e.g. Sup-T1, Table 1 ). The MT-2, MT-4, Molt-4, C8166 and H9 cell lines were the most sensitive. The MT-4 plaque assay was broadly of equivalent sensitivity to the MT-4 TCIDso assay of 12 strains of HIV-I, HIV-2 and SIV.
The MT-4 plaque assay can be used as a sensitive, quantitative assay for the detection of HIV-and SIV-neutralizing antibodies. The infection inhibition and plaque assays gave comparable neutralization titres for all sera. However, the pseudotype assay gave some discordant results; for example the neutralization titres of sera 1 and 5 for HTLV-IIIB were lower by the pseudotype assay than the other two assays, suggesting that the neutralization epitopes were presented in a different way on the chimeric VSV(HIV) particles. This interpretation is supported by the inability of the VSV pseudotype assay to detect the HIVneutralizing activity of an IgM monoclonal antibody directed to a defined epitope on gp41 (Dalgleish et al., 1988) .
The plaque assay offers a number of advantages over the VSV pseudotype assay: first, a wide range of HIV and SIV isolates can form plaques on MT-4 cells, obviating the need for the tedious and sometimes difficult preparation of VSV(HIV) pseudotype stocks of virus; secondly, performing the assay is relatively easy.
The pseudotype assay detects neutralization events occurring at the level of CD4 binding and subsequent membrane fusion, whereas the plaque assay has the potential of detecting neutralization events occurring after viral entry. Studies on the neutralization of influenza virus have shown that its neutralization is not always mediated through inhibition of attachment, penetration, uncoating or transport of the viral genome to the nucleus (Taylor & Dimmock, 1985) , illustrating the complexity of virus neutralization. Since the mechanisms of HIV neutralization are not yet known, the use of both assays in parallel may be useful for such studies. It has been shown that neutralizing monoclonal antibodies specific to the immunodominant loop on HIV-I gpl20 do not prevent virions binding to the CD4 receptor (Lindsley et al., 1988; Skinner et al., 1988) .
To date it has been difficult to establish infection inhibition-type neutralization assays for SIV, since the most commonly used CD4 ÷ T cell lines do not show cytopathic SIV infection. Most tests have relied upon the assay of inhibition of [3 H]thymidine incorporation in MT-4 cells (Harada et al., 1986) ; this is an indirect measurement of viral replication and leads to exceptionally high neutralization titres, since antibody is present throughout the assay and may neutralize output as well as input HIV. The plaque assay provides a quantal measurement of the inhibition of infection and may therefore prove useful in the analysis of sera from primates experimentally infected with SIV.
The plaque assay has proven useful in the biological cloning of HIV (Harada et al., 1987) and in the selection of neutralization-resistant escape mutants (J. McKeating, unpublished; S. Harada, personal communication) . We have also quantified soluble CD4 inhibition of HIV infectivity by both the MT-4 macroscopic plaque assay, the C8166 microscopic syncytial plaque assay and the VSV(HIV) pseudotype assay (Clapham et al., 1989) . The latter assay is better suited to microtitre plates than is the MT-4 plaque assay and is therefore suitable for reagents available only in small quantities or volumes. Plaque assays will also be useful for quantitative titration of other inhibitors and agents that act on early or late events in HIV infection.
